1
|
Catarino R, Alves L, Pereira J, Pereira D, Costa G, Cardoso A, Braga I, Freitas R, Correia T, Cerqueira M, Carmo Reis F, Lobo F, Morais A, Silva V, Magalhães S, Prisco R. Neoadjuvant chemotherapy in patients with urothelial bladder cancer. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03227-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
2
|
Austin R, Lobo F, Rajaguru S. GSM and Arduino Based Vital Sign Monitoring System. Open Biomed Eng J 2021. [DOI: 10.2174/1874120702115010078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Aims:
Analysis of the vital signs of patients can aid in early disease diagnosis and care. There are many illnesses which can be diagnosed and managed by monitoring this medical information periodically.
Background:
Detection of various early-stage medical diseases can be simply done by monitoring Human vital signs, as they show the standard body's essential functions, indicating the status of an individual's health condition.
Objective:
In many cases it so happens that patients do not receive appropriate medical treatment on time, as a result of which unexpected incidents happen due to ignorance of one’s health status. Since pulse rate and vital sign area unit are the foremost crucial parameters, an affordable device to detect such parameters is useful for human health.
Methods:
Photoplethysmography (PPG) is a photosensitive technique that measures difference in blood volume of the pulse (usually in the body's soft tissues) by specifically interfering with the differences in the photo-emitter's absorption, reflection, volume and dispersion of light, and then it is registered by the photoreceptor. Then, the PPG waveform reflects shifts in arterial blood supply. The waveform obtained with a pulse oximeter illuminates skin and processes variations in the absorption of light.
Results:
The embedded systems-Arduino, GSM module and the various sensors used in this research provide a simple monitoring method which does not require a smartphone or internet connectivity.
Conclusion:
This paper aims at illustrating the significance of constantly monitoring vital signs. The device proposed has been developed as an Arduino program that is straightforward and inexpensive, a conveyable system that acquires the vital signs data and sends a text message as warning messages during a health emergency.
Collapse
|
3
|
Catarino R, Alves L, Costa G, Pereira D, Pereira J, Cardoso A, Braga I, Freitas R, Correia T, Cerqueira M, Carmo Reis F, Lobo F, Morais A, Prisco R. Neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)01229-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Martin D, Lobo F, Lavison-Bompard G, Guérin T, Parinet J. Effect of home cooking processes on chlordecone content in beef and investigation of its by-products and metabolites by HPLC-HRMS/MS. Environ Int 2020; 144:106077. [PMID: 32866735 DOI: 10.1016/j.envint.2020.106077] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 08/17/2020] [Accepted: 08/17/2020] [Indexed: 06/11/2023]
Abstract
Chlordecone (CLD) is a toxic organochlorine pesticide frequently used in the French West Indies until 1993, resulting in a contamination of soil and food. This study assessed the behaviour of CLD residues and CLD processing factors (PFs) during four home cooking processes: cooking in a conventional oven ("oven"), frying ("pan"), cooking in a microwave oven ("microwave") and grilling ("grill"). These four processes were applied to six types of naturally contaminated beef (kidney, liver, rib, chuck, top-sirloin and sirloin). Targeted analyses with isotopic dilution were carried out by ID-HPLC-MS/MS to determine CLD concentrations before and after each cooking process and the corresponding processing factors. HPLC-HRMS/MS was used to find potential organochlorine degradation by-products and/or CLD metabolites present in samples by target, suspect and non-target screening. Cooking processes and especially microwave cooking led to a significant decrease in the CLD contained in beef (2% < PF < 17%). Traces of 5b-hydro-CLD and of another mono-hydro-CLD were found in the uncooked liver but no CLD degradation by-product was observed in the cooked liver.
Collapse
Affiliation(s)
- Deborah Martin
- Université de Paris-Est, ANSES, Laboratory for Food Safety, 94700 Maisons-Alfort, France
| | - Fiona Lobo
- Université de Paris-Est, ANSES, Laboratory for Food Safety, 94700 Maisons-Alfort, France
| | | | - Thierry Guérin
- Université de Paris-Est, ANSES, Laboratory for Food Safety, 94700 Maisons-Alfort, France
| | - Julien Parinet
- Université de Paris-Est, ANSES, Laboratory for Food Safety, 94700 Maisons-Alfort, France.
| |
Collapse
|
5
|
Quipildor AM, Ruiz‐Monachesi MR, Ruiz S, Hibbard TN, Valdecantos S, Lobo F. Male genitalia's evolutionary rate is higher than those of body traits: the case of two
Liolaemu
s lizards' group. J Zool (1987) 2020. [DOI: 10.1111/jzo.12836] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A. M. Quipildor
- CONICET‐ Instituto de Bio y Geo Ciencias del NOA (IBIGEO) Salta Argentina
| | | | - S. Ruiz
- CONICET‐ Instituto de Bio y Geo Ciencias del NOA (IBIGEO) Salta Argentina
| | - T. N. Hibbard
- CONICET‐ Instituto de Bio y Geo Ciencias del NOA (IBIGEO) Salta Argentina
| | - S. Valdecantos
- CONICET‐ Instituto de Bio y Geo Ciencias del NOA (IBIGEO) Salta Argentina
- Anatomía comparada Facultad de Ciencias Naturales Universidad Nacional de Salta (UNSa) Salta Argentina
| | - F. Lobo
- CONICET‐ Instituto de Bio y Geo Ciencias del NOA (IBIGEO) Salta Argentina
- Anatomía comparada Facultad de Ciencias Naturales Universidad Nacional de Salta (UNSa) Salta Argentina
| |
Collapse
|
6
|
Klink A, Han X, Lobo F, Szymialis R, Lam J, Feinberg B. FRI0096 CLINICAL BENEFITS REPORTED IN AMPLE TRIAL OBSERVED IN A REAL-WORLD (RW) COHORT OF US RHEUMATOID ARTHRITIS (RA) PATIENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Efficacy observed in controlled trials may not reflect RW effectiveness, given documented differences in patient populations and management.1Objectives:This study aimed to assess disease measures over time as measured in a trial setting (AMPLE) and in a separate RW observational setting, both among patients with RA treated with abatacept.Methods:The RW cohort comprised retrospective patient-level data abstracted by 31 community rheumatologists for adult RA patients treated with abatacept who had an anti-cyclic citrullinated peptide-2 titer ≥250 AU/mL. AMPLE was a phase III, randomized controlled trial of RA patients treated with abatacept that assessed disease measures over a 2-year follow-up. Data included demographics, treatments, labs, and disease measures (tender and swollen joint counts (TJC, SJC), C-reactive protein (CRP), American College of Rheumatology-20 (ACR20) and ACR50 at baseline and 3 and 6 months) and were summarized descriptively. Disease measures were evaluated across AMPLE and RW cohorts.Results:Of the 291 RW patients and 318 AMPLE patients, the majority were female (70%, 81%), white (72%, 81%), and RF-positive (91%, 76%), respectively (Table 1). The mean ages at abatacept initiation were 54.7 and 51.4 years old in RW and AMPLE, respectively. Concomitant corticosteroids (45%, 65%) and methotrexate (62%, 100%) were common in RW and AMPLE, respectively. All patients in AMPLE were biologic naïve, whereas 83% of RW patients had prior biologic use. AMPLE administered abatacept subcutaneously (SC), while 37% of RW patients received abatacept SC. Patients had median SJC and TJC of 6 and 8 in RW and 13 and 22 in AMPLE at abatacept initiation, respectively (Table 2). SJC (TJC) improved a median of 65% (60%) and 68% (66%) at 3 months and 75% (67%) and 76% (75%) at 6 months in RW and AMPLE, respectively (Fig 1). The majority of patients achieved ACR20 at 3 months (79% and 60%) and 6 months (88% and 66%) in RW and AMPLE, respectively, while 58% and 32% achieved ACR50 at 3 months and 67% and 45% at 6 months, respectively (Fig 2).Table 1:Patient Characteristics.RW cohort(n=291)AMPLE cohort(n=318)Female (n, %)205 (70%)259 (81%)White (n, %)209 (72%)257 (81%Age at abatacept initiation, years (mean, SD)54.7 (14.8)51.4 (12.6)RF-positive* (n, %)249 (91%)240 (76%)Concomitant medications (n, %) Corticosteroids†132 (45%)207 (65%) Methotrexate179 (62%)318 (100%)Prior biologic use (n, %)241 (83%)0 (0%)Route of administration (n, %) Intravenous183 (63%)0 (0%) Subcutaneous108 (37%)318 (100%)LEGEND: *among 274 with known RF status;†corticosteroids in AMPLE cohort at any time in the 2-year study periodTable 2.Changes in Disease Activity.RW cohort(n=291)AMPLE cohort(n=318)SJC (median) Baseline value613 3-month value24 6-month value13TJC (median) Baseline value822 3-month value37 6-month value25CRP, mg/dL (mean) Baseline value1.081.6 3-month value0.470.8 6-month value0.300.8ACR20 achieved (n, %) 3-month value194 (79%)191 (60%) 6-month value78 (88%)209 (66%)ACR50 achieved (n, %) 3-month value144 (58%)103 (32%) 6-month value60 (67%)144 (45%)LEGEND: values soonest after 3 months and value between 6-9 months used for RW cohort; values at days 85 and 197 used for AMPLE cohort.Conclusion:Despite differences in patient characteristics, improvements in SJC and TJC, as well as high rates of ACR20 and ACR50, were observed in both trial setting and RW settings. These improvements in disease activity were observed at similar magnitudes in both settings, demonstrating that trial efficacy is achievable in RW clinical practice with abatacept treatment.References:[1]Kilcher G, Hummel N, Didden EM, et al. Rheumatoid arthritis patients treated in trial and real-world settings: comparison of randomized trials with registries.Rheumatology. 2018;57(2):354-369.Disclosure of Interests:Andrew Klink Employee of: I am employed by Cardinal Health., Xue Han Employee of: BMS, Francis Lobo Shareholder of: Bristol-Myers Squibb (US), Employee of: Bristol-Myers Squibb (US), Rick Szymialis Shareholder of: BMS, Employee of: BMS, Jenny Lam Shareholder of: A few shares in Gilead in IRA account, Grant/research support from: Currently, a BMS fellowship (not a full-time employee), Bruce Feinberg Employee of: I am employed by Cardinal Health.
Collapse
|
7
|
Han X, Xia Q, Bao Y, Patel V, Roy A, Rajagopalan V, Lobo F. AB1344-HPR POOLED ANALYSIS OF ASSOCIATION BETWEEN ABATACEPT OR OTHER TARGET DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (TDMARD) AND TYPE 2 DIABETES MELLITUS (T2DM)-RELATED HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN TNFI-NAÏVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH T2DM. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Limited information is available on the impact of target disease-modifying anti-rheumatic drugs (tDMARD) on patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM).Objectives:The objective was to compare T2DM-related healthcare resource utilization (HCRU) and cost for TNF inhibitors (TNFi)-naive patients pooled from two commercial databases with RA and T2DM receiving abatacept, other non-TNFi, or TNFi.Methods:A retrospective, observational study was conducted with MarketScan and PharMetrics (January 2008-September 2018). The study population included TNFi-naïve adult patients with RA and T2DM newly initiating abatacept, TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or other non-TNFi (tocilizumab, anakinra, sarilumab, rituximab, tofacitinib). Date of tDMARD initiation was the index date. Patients had ≥2 RA diagnoses separated by ≥7 days, ≥1 T2DM diagnosis, and had ≥12 months of pre-index continuous enrollment. Follow-up ended at the end of patient insurance enrollment, study period or index treatment. T2DM-related HCRU and costs including inpatient stay, outpatient visits, ER visits, and pharmacy use were measured on a per-patient-per-month (PPPM) basis (2018 USD). Patients treated with abatacept were matched to TNFi and non-TNFi cohorts separately by propensity score adjusted with patients baseline comorbidities, HCRU, and costs.Results:A total of 16,236 patients meeting criteria were identified. Most patients were female (74.3%), and the overall average age of 55.4 years (Table 1). After matching, 850 pairs of abatacept vs non-TNFi patients, and 1,096 pairs of abatacept vs TNFi patients were included in the adjusted results. Patients initiating abatacept had $144 lower adjusted T2DM-related costs as compared to non-TNFi and $79 lower costs than TNFi cohorts (Table 2).Table 1.Patient CharacteristicsAbataceptn=1,134Non-TNFin=1,353TNFin=13,749TotalN=16,236Age, mean years (SD)58.5 (11.3)57.7 (11.2)54.9 (10.6)55.41 (10.7)Gender, female, n (%)936 (82.5)993 (73.4)10,142 (73.8)12,071 (74.3)CCI, mean (SD)2.2 (1.4)2.3 (1.4)1.8 (1.1)1.89 (1.14)DCSI, n (%) Cardiovascular361 (31.8)406 (30.0)2,500 (18.2)3,267 (20.1) Neuropathy294 (25.9)374 (27.6)3,161 (23.0)3,829 (23.6) Nephropathy146 (12.9)193 (14.3)1,151 (8.4)1,490 (9.2) PVD131 (11.6)155 (11.5)874 (6.4)1,160 (7.1) Retinopathy103 (9.1)119 (8.8)922 (6.7)1,144 (7.0) Cerebrovascular74 (6.5)102 (7.5)620 (4.5)796 (4.9) Metabolic9 (0.8)20 (1.5)141 (1.0)170 (1.0)CCI: Charlson comorbidity index; DCSI: diabetes complications severity index; PVD: peripheral vascular disease.Table 2.Adjusted T2DM-related HCRU and Costs after Propensity Score MatchingAbataceptn=850Non-TNFin=850Diff (ABA- Non-TNF)Abataceptn=1,096TNFin=1,096Diff (ABA- TNF)T2DM-related HCRU (per 1000 Patients per Month)Number of Hospitalizations13.920.4-6.5*12.614.9-2.3*Number ofER Visits22.016.15.9*18.416.32.0*Number ofOutpatient Visits311334.8-23.7*299.3286.912.4T2DM-related Costs (PPPM $)Inpatient Costs507535-28413475-62ER Costs271710*2225-3Outpatient Costs190323-13318617016*Pharmacy Costs1071007*97128-31Total Costs831975-144719798-79**P<0.05Conclusion:TNFi-naive RA patients with T2DM newly initiating abatacept had lower adjusted rates of T2DM-related hospitalizations compared to patients who initiated a non-TNFi or a TNFi. Total costs were lower among patients initiating abatacept vs. patients who initiated a non-TNFi or a TNFi. Findings suggest that initial abatacept among TNFi-naïve patients may be able to reduce healthcare utilization arising from T2DM complications and reduce T2DM-related costs in RA patients.Disclosure of Interests:Xue Han Employee of: BMS, Qian Xia Shareholder of: I own shares of Bristol-Myers Squibb Company, Employee of: I am a paid employee of Bristol-Myers Squibb Company, Ying Bao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Vardhaman PATEL Employee of: Bristol Myers Squibb, Amrina Roy Employee of: Mu-Sigma, Varshini Rajagopalan Employee of: Mu-Sigma, Francis Lobo Shareholder of: Bristol-Myers Squibb (US), Employee of: Bristol-Myers Squibb (US)
Collapse
|
8
|
Park SH, Han X, Lobo F, Nanji S, Patel D. AB1164 A COST PER RESPONDER ANALYSIS OF ABATACEPT VERSUS ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AMONG PATIENTS WITH SHARED EPITOPE (SE) POSITIVITY FROM A UNITED STATES PAYER PERSPECTIVE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The shared epitope (SE) is a significant genetic risk factor for rheumatoid arthritis (RA), and it has been proposed to be associated with T-cell activation and the production of anti-citrullinated protein antibody (ACPA).1-3The results from the Early AMPLE trial, a head-to-head trial comparing the efficacy of abatacept versus adalimumab among early moderate-to-severe RA patients with positive ACPA (ACPA+) and rheumatoid factor (RF), showed that at week 24, patients with SE positivity (SE+) responded better to abatacept compared to adalimumab across all efficacy measures evaluated (ACR20 [American College of Rheumatology], ACR50, ACR70, DAS[disease activity score]28-CRP[C-reactive protein]).4Objectives:To compare the cost per responder (CPR) between abatacept and adalimumab among RA patients with SE+ at week 24 using the Early AMPLE trial data from a United States (US) payer perspective.Methods:A CPR analysis was conducted for RA patients with SE+, ACPA+, and RF. Responders were defined as patients achieving ACR20, ACR50, ACR70, or DAS28-CRP ≤2.6 and efficacy data was sourced from the trial (Figure 1).4Approved product labels were referenced for treatment dosing regimen and wholesale acquisition cost was used to calculate pharmacy cost.5A real-world rebate scenario was considered for adalimumab (30%) to reflect the real-world pricing in the US market. The CPR was calculated as the total pharmacy cost divided by the proportion of responders.Results:The total pharmacy cost at week 24 was $26,273 per patient for abatacept and $21,731 per patient for adalimumab. With achieving ACR70 as the definition of responder, the CPR at 24-week was $46,337 for abatacept and $74,935 for adalimumab, a difference of $28,598 (Table 1). The CPR was consistently lower for abatacept compared to adalimumab across all clinical measures, with difference ranging from $7,099 to $43,609.Table 1.Overall cost per responder resultsAbataceptAdalimumabDifferenceACR20$30,303.74$37,403.06-$7,099.32ACR50$34,254.68$48,077.83-$13,823.15ACR70$46,337.46$74,935.10-$28,597.64DAS28-CRP ≤2.6$52,546.68$96,155.65-$43,608.97Conclusion:While the pharmacy cost was higher for abatacept compared to adalimumab driven by the rebate, due to its higher clinical efficacy, the CPR was consistently lower for SE+ RA patients treated with abatacept. The results may be useful for US healthcare decision makers in understanding how to optimize treatment for SE+ RA patient while minimizing costs in today’s budget constrained environment.References:[1]Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.Arthritis and rheumatism. 1987;30(11):1205-13.[2]Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope.Curr Opin Rheumatol. 2010;22(3):293-8.[3]Sakkas LI, Bogdanos DP, Katsiari C, et al. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment.Autoimmun Rev. 2014;13(11):1114-20.[4]Fleischmann R, Weinblatt M, Ahmad H, et al. Efficacy of abatacept and adalimumab in patientsn with early rheumatoid arthritis with multiple poor prognostic factors: post hoc analysis of a randomized controlled clinical trial (AMPLE).Rheumatol Ther. 2019;6(4): 559-571.[5]Truven Health Analytics. Redbook online. Accessed October 11, 2019.Disclosure of Interests:Sang Hee Park Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Inc. for this study, Xue Han Employee of: BMS, Francis Lobo Shareholder of: Bristol-Myers Squibb (US), Employee of: Bristol-Myers Squibb (US), Sakina Nanji Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Inc. for this study, Dipen Patel Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Inc. for this study
Collapse
|
9
|
Osorio-Silla I, Gómez Valdazo A, Sánchez Méndez JI, York E, Díaz-Almirón M, Gómez Ramírez J, Rivas Fidalgo S, Oliver JM, Álvarez CM, Hardisson D, Díaz Miguel M, Lobo F, Díaz Domínguez J. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer? Ann R Coll Surg Engl 2019; 101:186-192. [PMID: 30421628 PMCID: PMC6400929 DOI: 10.1308/rcsann.2018.0196] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/10/2018] [Indexed: 12/28/2022] Open
Abstract
INTRODUCTION Recent prospective studies support the feasibility of performing sentinel lymph node biopsy following neoadjuvant chemotherapy in initially fine-needle aspiration cytology or ultrasound-guided biopsy-proven node-positive breast cancer. The main aid is to identify preoperative features that help us predict a complete axillary response to neoadjuvant chemotherapy in these patients and thus select the candidates for sentinel lymph node biopsy post-neoadjuvant chemotherapy to avoid unnecessary axillary lymphadenectomy. MATERIALS AND METHODS A retrospective observational study with a total of 150 patients, biopsy-proven node-positive breast cancer who underwent neoadjuvant chemotherapy followed by breast surgery and axillary lymphadenectomy were included and retrospectively analysed. A predictive model was generated by a multivariate logistic regression analysis for pathological complete response-dependent variable. RESULTS The response of the primary lesion to neoadjuvant chemotherapy according to post-treatment magnetic resonance imaging, Her2/neu overexpression and a low estrogen receptor expression are associated with a higher rate of nodal pathologically complete response. The multivariant model generated a receiver operating characteristic curve with an area under the curve of 0.79 and a confidence interval of 0.72-0.87 at a 95% level of significance. CONCLUSIONS This model could be a helpful tool for the surgeon to help in predicting which cases have a higher likelihood of achieving a pathologically complete response and therefore selecting those who may benefit from a post-neoadjuvant chemotherapy sentinel lymph node biopsy and avoid unnecessary axillary lymphadenectomy.
Collapse
Affiliation(s)
- I Osorio-Silla
- Department of Surgery, Hospital Universitario La Pa , Madrid , Spain
| | - A Gómez Valdazo
- Department of Surgery, Hospital Universitario Fundación Jiménez Díaz , Madrid , Spain
| | - J I Sánchez Méndez
- Department of Gynaecology and Obstetrics, Hospital Universitario La Paz , Madrid , Spain
| | - E York
- Department of Surgery, Hospital Universitario La Pa , Madrid , Spain
| | - M Díaz-Almirón
- Department of Surgery, Hospital Universitario La Pa , Madrid , Spain
| | - J Gómez Ramírez
- Department of Surgery, Hospital Universitario Fundación Jiménez Díaz , Madrid , Spain
| | - S Rivas Fidalgo
- Department of Surgery, Hospital Universitario Fundación Jiménez Díaz , Madrid , Spain
| | - J M Oliver
- Department of Radiology, Hospital Universitario La Paz , Madrid , Spain
| | - C M Álvarez
- Department of Gynaecology and Obstetrics, Hospital Universitario La Paz , Madrid , Spain
| | - D Hardisson
- Department of Pathology, Hospital Universitario La Paz , Madrid , Spain
| | - M Díaz Miguel
- Department of Surgery, Hospital Universitario Fundación Jiménez Díaz , Madrid , Spain
| | - F Lobo
- Department of Oncology, Hospital Universitario Fundación Jiménez Díaz , Madrid , Spain
| | - J Díaz Domínguez
- Department of Surgery, Hospital Universitario La Pa , Madrid , Spain
| |
Collapse
|
10
|
Azmy V, Brooks J, Lobo F. TWENTY-FIVE YEAR-OLD MALE ATHLETE WITH COUGH, EXERTIONAL DYSPNEA, AND HISTORY OF PNEUMONIA. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Brooks J, Helgeson A, Lobo F. RESOLUTION OF MILK-PROTEIN ALLERGY AFTER HEMATOPOIETIC STEM CELL TRANSPLANT IN A PATIENT WITH IPEX SYNDROME. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Quipildor M, Quinteros A, Lobo F. Structure, variation, and systematic implications of the hemipenes of liolaemid lizards (Reptilia: Liolaemidae). CAN J ZOOL 2018. [DOI: 10.1139/cjz-2017-0245] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The structure of copulatory organs is widely used in systematics for both differentiating species and for studying phylogenetic relationships. We describe the hemipenes of 42 species belonging to the genus Liolaemus, representing most of their internal groups. We reported 42 characters, the majority not published previously. We constructed a metatree based on previously proposed phylogenetic studies and optimized the hemipenial characters in this topology. Among the most informative characters are presence or absence of flounces or calyces on the sulcate face, ornamentation of the apex, presence or absence of an asulcate face prominence, and presence of a thickening on the proximal region of the asulcate face. Furthermore, we performed a phylogenetic analysis exclusively with the hemipenial characters, not with the intention of making a phylogeny based on this single set of characters, but rather to demonstrate their significance for the reconstruction of relationships in Liolaemus. The obtained results show that the main clades are recovered. We also compared the hemipenial morphology between closely related species to evaluate its taxonomic importance. We conclude that in Liolaemus, the hemipenes can be used both for the differentiation of species and to provide additional evidence for establishing their phylogenetic relationships.
Collapse
Affiliation(s)
- M. Quipildor
- IBIGEO (Instituto Bio y Geociencias del NOA). CONICET–UNSa. 9 de Julio 14. Rosario de Lerma, CP 4405. Salta, Argentina
- IBIGEO (Instituto Bio y Geociencias del NOA). CONICET–UNSa. 9 de Julio 14. Rosario de Lerma, CP 4405. Salta, Argentina
| | - A.S. Quinteros
- IBIGEO (Instituto Bio y Geociencias del NOA). CONICET–UNSa. 9 de Julio 14. Rosario de Lerma, CP 4405. Salta, Argentina
- IBIGEO (Instituto Bio y Geociencias del NOA). CONICET–UNSa. 9 de Julio 14. Rosario de Lerma, CP 4405. Salta, Argentina
| | - F. Lobo
- IBIGEO (Instituto Bio y Geociencias del NOA). CONICET–UNSa. 9 de Julio 14. Rosario de Lerma, CP 4405. Salta, Argentina
- IBIGEO (Instituto Bio y Geociencias del NOA). CONICET–UNSa. 9 de Julio 14. Rosario de Lerma, CP 4405. Salta, Argentina
| |
Collapse
|
13
|
Nadkarni A, Lobo F, Juday T. AB1028 Rates of Switching and Healthcare Costs Associated with Switching Biological Disease-Modifying Antirheumatic Drugs in A Commercial Population: Evidence from Real-World Observational Studies. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, Henrique R, Jerónimo C. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 2013; 109:2646-53. [PMID: 24129247 PMCID: PMC3833202 DOI: 10.1038/bjc.2013.552] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 08/13/2013] [Accepted: 08/19/2013] [Indexed: 12/12/2022] Open
Abstract
Background: Renal cell tumours (RCTs) are clinically, morphologically and genetically heterogeneous. Accurate identification of renal cell carcinomas (RCCs) and its discrimination from normal tissue and benign tumours is mandatory. We, thus, aimed to define a panel of microRNAs that might aid in the diagnostic workup of RCTs. Methods: Fresh-frozen tissues from 120 RCTs (clear-cell RCC, papillary RCC, chromophobe RCC (chRCC) and oncocytomas: 30 cases each), 10 normal renal tissues and 60 cases of ex-vivo fine-needle aspiration biopsies from RCTs (15 of each subtype validation set) were collected. Expression levels of miR-21, miR-141, miR-155, miR-183 and miR-200b were assessed by quantitative reverse transcription–PCR. Receiver operator characteristic curves were constructed and the areas under the curve were calculated to assess diagnostic performance. Disease-specific survival curves and a Cox regression model comprising all significant variables were computed. Results: Renal cell tumours displayed significantly lower expression levels of miR-21, miR-141 and miR-200b compared with that of normal tissues, and expression levels of all miRs differed significantly between malignant and benign RCTs. Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly, miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis. Conclusion: The miR-141 or miR-200b panel accurately distinguishes RCC from normal kidney and oncocytoma in tissue samples, discriminating from normal kidney and oncocytoma, whereas miR-21, miR-141 and miR-155 convey prognostic information. This approach is feasible in fine-needle aspiration biopsies and might provide an ancillary tool for routine diagnosis.
Collapse
Affiliation(s)
- R M Silva-Santos
- 1] Cancer Epigenetics Group, Research Center of the Portuguese Oncology Institute, Rua Doutor António Bernardino Almeida, 4200-072 Porto, Portugal [2] Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Rosenblatt L, Lobo F, Cockrum P, Wang L, Alemao E, Baser O, Yuce H. FRI0550 Biologic switching rates among patients with rheumatoid arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Domine M, Rojo F, Izarzugaza Y, Zazo S, Lobo F, Aceñero MF, Madoz J, Casado V, Rubio G, Garcia-Foncillas J. Kras Status as Predictive Marker of Response and Time to Progression in EGFR Wild-Type Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Platin-Docetaxel-Bevacizumab. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32758-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Teixeira A, Silva J, Ferreira M, Marques I, Gomes M, Mauricio J, Lobo F, Medeiros R. 891 Circulating MicroRNA-222 in Plasma – a Potential Biomarker for Renal Cell Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71523-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
López-Gómez M, Ortega C, Suárez I, Serralta G, Madero R, Gómez-Raposo C, Sereno M, Casado E, Espinosa E, Lobo F, Feliu J. Internet use by cancer patients: should oncologists ‘prescribe’ accurate web sites in combination with chemotherapy? A survey in a Spanish cohort. Ann Oncol 2012; 23:1579-85. [DOI: 10.1093/annonc/mdr532] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012; 23:1156-1164. [PMID: 21908496 DOI: 10.1093/annonc/mdr361] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized. PATIENTS AND METHODS Quantitative expression of PARP-1 protein was assayed by a specific immunohistochemical signal intensity scanning assay in a range of normal to malignant breast lesions, including a series of patients (N = 330) with operable breast cancer to correlate with clinicopathological factors and long-term outcome. RESULTS PARP-1 was overexpressed in about a third of ductal carcinoma in situ and infiltrating breast carcinomas. PARP-1 protein overexpression was associated to higher tumor grade (P = 0.01), estrogen-negative tumors (P < 0.001) and triple-negative phenotype (P < 0.001). The hazard ratio (HR) for death in patients with PARP-1 overexpressing tumors was 7.24 (95% CI; 3.56-14.75). In a multivariate analysis, PARP-1 overexpression was an independent prognostic factor for both disease-free (HR 10.05; 95% CI 5.42-10.66) and overall survival (HR 1.82; 95% CI 1.32-2.52). CONCLUSIONS Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Animals
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/diagnosis
- Breast Neoplasms/metabolism
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Cell Nucleus/metabolism
- Cell Nucleus/pathology
- Cells, Cultured
- Disease Progression
- Embryo, Mammalian
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Mice
- Mice, Knockout
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases/genetics
- Poly(ADP-ribose) Polymerases/metabolism
- Prognosis
- RNA, Small Interfering/pharmacology
- Survival Analysis
- Up-Regulation/drug effects
- Up-Regulation/genetics
Collapse
Affiliation(s)
- F Rojo
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Department of Pathology, Hospital del Mar, Barcelona; Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - J García-Parra
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - S Zazo
- Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - I Tusquets
- Medical Oncology Department, Hospital del Mar, Barcelona
| | - J Ferrer-Lozano
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia
| | - S Menendez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - P Eroles
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia
| | - C Chamizo
- Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - S Servitja
- Medical Oncology Department, Hospital del Mar, Barcelona
| | | | - F Lobo
- Department of Oncology, IIS-Fundación Jiménez Díaz, Madrid
| | - B Bellosillo
- Department of Pathology, Hospital del Mar, Barcelona
| | - J M Corominas
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Department of Pathology, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona
| | - J Yelamos
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Immunology Department, Hospital del Mar, Barcelona
| | - S Serrano
- Department of Pathology, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona
| | - A Lluch
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia; Department of Medicine, Valencia Central University, Valencia, Spain
| | - A Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - J Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona.
| |
Collapse
|
20
|
Brandão PG, Lobo S, Nassau Machado M, Duarte J, Lobo F, Sakr Y. Dexmedetomidine is associated with better outcomes in patients undergoing cardiac surgery. Crit Care 2012. [PMCID: PMC3363745 DOI: 10.1186/cc10934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
21
|
Teixeira A, Marques I, Ferreira M, Gomes M, Lobo F, Medeiros R. 7155 POSTER Is Epidermal Growth Factor Receptor R497K Polymorphism in Renal Cell Carcinoma a Molecular Marker of Advanced Disease? Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72070-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
22
|
Marques I, Teixeira A, Ferreira M, Lobo F, Assis J, Medeiros R. 7116 POSTER Influence of BIRC5 -31G/C Polymorphism in Renal Cell Carcinoma (RCC) Development and Metastization. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72031-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Cunha V, Ribeiro R, Azevedo A, Monteiro C, Pina F, Fraga A, Calais da Silva F, Lobo F, Medeiros R. 96 Adiponectin functional polymorphisms and haplotype are associated with prostate cancer aggressiveness and to hormonal castration resistance. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70904-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
24
|
Teixeira A, Ribeiro R, Gomes M, Pereira C, Lobo F, Fraga A, Calais-da-Silva F, Pina F, Medeiros R. 89 Influence of functional genetic variants of TGFβ1/TGFβR2 pathway in prostate cancer development. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70898-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
25
|
Monteiro C, Ribeiro R, Azevedo A, Cunha V, Fraga A, Pina F, Calais da Silva F, Lobo F, Medeiros R. 97 Non-synonym leptin receptor genetic variants, prostate cancer susceptibility and aggressiveness. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70905-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
26
|
Domine M, Gonzalez-Larriba JL, Lopez-Vilariño J, Alfonso R, Leon A, Puente J, Casado-Echarren V, Rodriguez L, Rubio G, Lobo F. Weekly topotecan-gemcitabine for pretreated small cell lung cancer (SCLC) patients (pts): A phase II study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Azevedo A, Ribeiro R, Monteiro C, Cunha V, Francisco N, Fraga A, Pina F, Calais-da-Silva E, Lobo F, Medeiros R. 7022 Genetic profile of IL-6/IL6R pathway predicts susceptibility, agressiveness and response to hormonal treatment in prostate cancer patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71400-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
28
|
Teixeira A, Ribeiro R, Morais A, Lobo F, Fraga A, Calais-da-Silva F, Calais-da-Silva F, Pina F, Medeiros R. Proliferative/Angiogenic genetic profile is associated with progression-free-interval in androgen blockade treated prostate cancer patients. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71763-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
29
|
López M, Feliú J, Espinosa E, Castelo B, de Castro J, Belda-Iniesta C, Sereno M, Madero R, Lobo F, González Barón M. Use of Internet among cancer patients and their relatives in Spain. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Teixeira A, Ribeiro R, Cardoso D, Pinto D, Morais A, Lobo F, Calais-da-Silva F, Calais-da-Silva F, Medeiros R. 509 POSTER Epidermal growth factor (EGF) +61 A/G functional genetic polymorphism influences disease-free interval in androgen blockade treated prostate cancer patients. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70448-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
31
|
Lima L, Morais A, Lobo F, Calais-da-Silva F, Calais-da-Silva F, Santos L, Medeiros R. 536 POSTER Apoptosis in Bladder and prostate cancer: The role of FAS and FASL polymorphisms. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70475-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
32
|
Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 2007; 11:94-8. [PMID: 17667965 DOI: 10.1038/sj.pcan.4501002] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The role of FAS polymorphisms in prostate cancer has not been studied. Using the PCR-based restriction fragment-length polymorphism methodology, we evaluated FAS gene locus -670 genotypes in DNA from 904 men: 657 prostate cancer patients and 247 healthy controls. We found that carriers of AG or GG genotypes have a statistically significant protection (odds ratio (OR)=0.30; confidence interval (CI): 0.20-0.44 and OR=0.22; CI: 0.12-0.74, respectively) for disease with extra-capsular invasion. Taken together, a 72% protection was found for G allele carriers (OR=0.28; CI: 0.19-0.41). Fas exist as membrane-bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand, soluble Fas (sFas) bind to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form.
Collapse
Affiliation(s)
- L Lima
- Molecular Oncology Unit, Instituto Português de Oncologia, Porto, Portugal
| | | | | | | | | | | |
Collapse
|
33
|
Estévez LG, Martín M, Alba E, Colomer R, Lobo F, Lluch A, Adrover E, Albanell J, Barnadas A, García-Mata J, Llombart A, Muñoz M, Rodríguez C, Sánchez-Rovira P, Seguí MA, Tusquets I. Current controversies in the management of early breast cancer. Clin Transl Oncol 2007; 9:375-84. [PMID: 17594952 DOI: 10.1007/s12094-007-0070-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Medical professionals in general, and medical oncologists in particular, have highly stressful practices because they are under constant pressure to have the highest-quality, up-to-date evidence available in order to make the right decision for each individual patient. From a practical point of view, being updated on oncological and other medical specialties may seem an insurmountable task because the number of scientific publications has increased dramatically. The use of systematic reviews of randomised controlled trials or the application of results obtained from high-quality randomised controlled trials are some of the most common ways to address this need. Unfortunately, they do not cover all complex clinical situations that the majority of medical oncologists face in their outpatient consultations. In this review, we report the conclusions achieved in a multiexpert meeting where five important controversies in the treatment of breast cancer were analysed. Five highly experienced medical oncologists were required to defend an affirmative answer and another five were required to defend a negative answer for each of the clinical questions. After that, a one-day meeting was organised to debate each clinical question and to reach a consensus. We report here the content of this multi-expert meeting along with the conclusions drawn.
Collapse
Affiliation(s)
- L G Estévez
- Centro Integral Oncológico Clara Campal, C/Oña, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Estévez LG, Sánchez-Rovira P, Dómine M, León A, Calvo I, Jaén A, Casado V, Rubio G, Díaz M, Miró C, Lobo F, Carrasco E, Casillas M, San Antonio B. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study. Clin Transl Oncol 2007; 9:317-22. [PMID: 17525042 DOI: 10.1007/s12094-007-0059-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION The purpose of this phase II study was to evaluate the efficacy and safety of neoadjuvant docetaxel/gemcitabine treatment in a biweekly regimen. MATERIALS AND METHODS Patients with stage II/III breast cancer were treated with docetaxel (65 mg/m(2)) followed by gemcitabine (2500 mg/m(2)) every 2 weeks for 6 cycles. Patients with a clinical response or stable disease underwent mastectomy or breast-conserving surgery plus axillary dissection. After surgery, patients received 4 cycles of standard doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every 21 days. RESULTS Thirty-five patients were included in the trial. The overall response rate was 71.4% (95% CI: 53.7-85.4), with 8 complete and 17 partial responses. Breast conservation was possible in 59% of the patients. Toxicity was manageable. CONCLUSIONS We consider biweekly docetaxel and gemcitabine could be an active and tolerable regimen option in the neoadjuvant setting sequentially with standard adjuvant doxorubicin-cyclophosphamide in patients with stage II or III breast cancer.
Collapse
|
35
|
Escobar Y, Domine M, Valcarcel F, Contreras J, Lobo F. Evaluation of sensitivity to change of the MPAC scale, validated in Spanish, in pain measurement in cancer patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19567 Background: The Memorial Pain Assessment Card (MPAC) allows an easy measurement of oncologic pain in the clinical practice. In 2004, a Spanish version of the MPAC scale was validated in cancer pain. The goal of the present work was to evaluate the sensitivity to change of the validated Spanish version by oncologic patients. Methods: Epidemiological, prospective, 2-months multicenter study, conducted at 4 services of oncology. The included patients suffered continuous chronic cancer pain and were in a susceptible situation of change (pain intensity ≥ 3 in a Visual Analogue Scale). The MPAC card was administered at baseline and at 1 and 2 months, including the 4 subscales (pain relief [VASPR], pain intensity measured by VAS [VASPI] and by an 8-items descriptors subscale [Tursky], and psychological distress [VASMOOD]). Data about clinical situation and satisfaction of the patient and the health care professionals with the MPAC card was also collected. Sensitivity to change was evaluated by comparing 2-months versus baseline results in the MPAC subscales. Results: Fifty-four patients with oncologic pain (76% men) with a mean (SD) age of 57(11) years were included. 74% of patients presented metastasis, and in 80% of cases the treatment was palliative. All the MPAC VAS subscales showed sensitivity to change across the 2-months period: mean VASPI at baseline 6.6(1.7) vs 3.5(2.0) at 2 months (p<0.0001, Wilcoxon test [WX]); VASPR 4.5(1.9) vs 6.3(2.3) (p<0.0001 [WX]); VASMOOD 5.5(2.1) vs 4.0(2.1) (p=0.0008 [WX]). Furthermore, 90.5% of patients showed changes in Tursky subscale (78.6% less pain, 11.9% increased pain), being these changes significantly associated with VASPI scores (p=0.0006, Kruskal-Wallis test). Both patients and medical personnel agreed in the card use facility (63% and 71% of cases, respectively). Conclusions: The Spanish MPAC version has demonstrated sensitivity to change in all the MPAC subscales (pain relief, pain intensity and psychological distress). Its facility of administration may allow a useful and quick evaluation of the cancer pain in the clinical practice. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Escobar
- Hospital General Universitario Gregorio Marañon, Madrid, Spain; Fundacion Jimenez Diaz, Madrid, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Carlos Haya, Malaga, Spain
| | - M. Domine
- Hospital General Universitario Gregorio Marañon, Madrid, Spain; Fundacion Jimenez Diaz, Madrid, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Carlos Haya, Malaga, Spain
| | - F. Valcarcel
- Hospital General Universitario Gregorio Marañon, Madrid, Spain; Fundacion Jimenez Diaz, Madrid, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Carlos Haya, Malaga, Spain
| | - J. Contreras
- Hospital General Universitario Gregorio Marañon, Madrid, Spain; Fundacion Jimenez Diaz, Madrid, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Carlos Haya, Malaga, Spain
| | - F. Lobo
- Hospital General Universitario Gregorio Marañon, Madrid, Spain; Fundacion Jimenez Diaz, Madrid, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Carlos Haya, Malaga, Spain
| |
Collapse
|
36
|
Herrero J, Gómez-Codina J, Provencio M, Rueda A, Llanos M, Lobo F, Vicente D, Sabín P, García-Arroyo F, Iglesias C. First efficacy assessment of a phase II study with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone plus rituximab, administered every two weeks (R-COMP-14) as primary treatment for NHL. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18519] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18519 Background: R-CHOP is the standard treatment for CD20+ aggressive B-cell non-Hodgkin lymphoma (DLBCL). Dose dense regimens have shown better outcome and acceptable tolerability compared to standard. Liposomal doxorubicin has demonstrated significant less cardiotoxicity and acute toxicity when compared with standard doxorubicin. The aim of the study is to assess the efficacy and safety of the R- COMP-14 (Myocet™-modified CHOP) in newly diagnosed aggressive DLBCL. Pegfilgrastim was used to provide prophylactic bone marrow support. Methods: Patients (Pts) with stages III, IV or I, II (IPI = 1) were included in this single arm, multicentric, 2-step (Simon design) phase II trial. Treatment: eight biweekly cycles of liposomal doxorubicin 50 mg/m2, cyclophosphamide 750mg/m2, vincristine 1.4 mg/m2 (max. 2mg), rituximab 375 mg/m2 and prednisone 100 mg/d d1–5. Pegfilgrastim was administered on day 2 at standard dose. Interim analysis shows: Twenty-six out of 28 Pts were evaluable for efficacy. Median age: 51 y (28 - 64). Ann Arbor stage: I-II (IPI = 1) 42%, III 29%, IV 29%. Extranodal involvement: 50%. Median basal LVEF was 66% (range 44 - 80). Results: The overall response rate was 84% (CR 64% and PR 20%). Three (12%) Pts had PD and 1 (4%) SD. Median n° cycles was 8 (2-8); the median relative dose intensity per week was 93.5%. Only 4.8% of cycles were delayed and 4.2% of the cycles were administered with dose reduction due to related adverse events. Grade 3–4 neutropenia and thrombocytopenia were observed in 4.0% and 0.6% of cycles respectively. Febrile neutropenia experienced in 3.3% of cycles. Non-hematological G3–4 toxicities per cycles were hepatic (1.7%), emesis (1.2%) and G3 neurotoxicity, asthenia and infection (0.6% each). No other relevant toxicities were observed. Median LVEF after completion of treatment was 63% (range 52 - 76), there was no cardiac clinical event related to the treatment, nor irreversible toxicities. Conclusions: This Interim analysis confirmed the efficacy and safety of the dose-dense regimen in order to continue with the second step of the study. R-COMP-14 treatment with pegfilgrastim bone marrow support warrants further exploration. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Herrero
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - J. Gómez-Codina
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - M. Provencio
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - A. Rueda
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - M. Llanos
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - F. Lobo
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - D. Vicente
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - P. Sabín
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - F. García-Arroyo
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| | - C. Iglesias
- Hosp Gral Alicante, Alicante, Spain; Hosp Univ La Fe, Valencia, Spain; Hosp Puerta de Hierro, Madrid, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp Univ Canarias, Tenerife, Spain; Fund Jiménez Díaz, Madrid, Spain; Hosp J.R. Jiménez, Huelva, Spain; Hosp G. Marañón, Madrid, Spain; Hosp Pontevedra, Pontevedra, Spain; Hosp Virgen del Rocío, Sevilla, Spain
| |
Collapse
|
37
|
Lima L, Calais da Silva FM, Calais da Silva FE, Morais A, Lobo F, Medeiros R. Fas-670 polymorphism and prostate cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21028 Background: The FAS/FASL system is one of the major pathways in apoptosis and is important to regulate cell proliferation and tumor cell growth. Functional promoter polymorphisms of FAS gene (FAS -670 A/G) alter the transcriptional activity. The role of FAS polymorphisms in prostate cancer has not been studied. Methods: DNA extracted from peripheral blood from 529 prostate cancer patients and from 247 healthy controls was analysed by Polymerase Chain Reaction - Restriction Fragment Length Polymorphism (PCR-RFLP) for FAS gene locus -670 genotypes. Results: We found that the AG and GG genotypes represent significantly protection (OR=0.41; confidence interval (CI): 0.26–0.65 and OR=0.39; CI: 0.21–0.74, respectively) for extracapsular invasion. Taken this genotypes together, a significantly protection was found for G allele carriers (OR=0.41; CI: 0.27–0.63). Conclusions: It is well known that G allele reduces the transcriptional activity of FAS gene. Fas exist as membrane bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptor trigger apoptosis and in other hand soluble Fas (sFas), which lacks transmembrane domain, binds to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. It is reported that serum sFas is elevated in prostate cancer and associated with advanced disease. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Lima
- Portuguese Institute of Oncology, O'Porto, Portugal; Centro Hospitalar de Lisboa, Lisbon, Portugal
| | - F. M. Calais da Silva
- Portuguese Institute of Oncology, O'Porto, Portugal; Centro Hospitalar de Lisboa, Lisbon, Portugal
| | - F. E. Calais da Silva
- Portuguese Institute of Oncology, O'Porto, Portugal; Centro Hospitalar de Lisboa, Lisbon, Portugal
| | - A. Morais
- Portuguese Institute of Oncology, O'Porto, Portugal; Centro Hospitalar de Lisboa, Lisbon, Portugal
| | - F. Lobo
- Portuguese Institute of Oncology, O'Porto, Portugal; Centro Hospitalar de Lisboa, Lisbon, Portugal
| | - R. Medeiros
- Portuguese Institute of Oncology, O'Porto, Portugal; Centro Hospitalar de Lisboa, Lisbon, Portugal
| |
Collapse
|
38
|
Lobo S, Oliveira N, Lobo F, Rezende E, Borges B, Cunrath G, Silva J, Ronchi L. Oxygen delivery optimization using lithium indicator dilution and pulse power analysis during major surgery in high-risk patients. Crit Care 2007. [PMCID: PMC4095358 DOI: 10.1186/cc5465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Batista N, Estevez L, Sánchez-Rovira P, Velasco A, Dómine M, Lobo F, Oramas J, Cruz J. Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10693 Background: X monotherapy is consistently effective and very well tolerated in pretreated MBC. N is also commonly used in this indication. In several studies, the combination of X + N led to response rates ranging from 43–67% in first-line MBC. As there are few data on the combination in pts with pretreated MBC, we evaluated the efficacy and safety of X + N in a multicenter phase II trial of pts previously treated with anthracycline- and taxane-containing regimens. Methods: Women >18 years of age with pretreated MBC, PS 0–2 and adequate organ function were enrolled to receive a 3-weekly regimen of XN: X 1000mg/m2 twice daily on days 1–14 and N 25mg/m2 on days 1&8, every 3 weeks up to a maximum of 6 cycles, disease progression or unacceptable toxicities. Results: A total of 32 pts were enrolled, median age 58 years (range 41–77), PS 0(74%), 1(19%), postmenopausal (61%). The most frequent sites of metastases were: liver (68%), nodes (36%), lung (36%). 58% of pts had ≥2 metastatic sites. 27 patients (87%) previously failed on anthracycline and taxane chemotherapy regimens. 152 cycles were administered with a median of 3 cycles/pt (range 1–10). Median relative dose intensity was 0.86 (0.51–1.01] for N and 0.85 (0.26–1.03] for X. All pts were evaluable for safety. The most common grade 3/4 clinical adverse events were vomiting (15%), asthenia (9%), and hand-foot syndrome (6%). Grade 3/4 hematological toxicities were: neutropenia (47%), leucopenia (9%), thrombocytopenia (3%). One pt died due to septic shock after the first cycle. 29 pts are evaluable for efficacy: the overall response rate was 52% (4 CR, 11 PR), with stable disease in 8 pts (28%). Median TTP was 7.5 months [95% CI, 5.7–9.8]. Conclusions: Our preliminary data indicate that the combination of X and N has promising clinical activity and good safety in pts with MBC who have failed prior taxane- and anthracycline-containing regimens. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Batista
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - L. Estevez
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - P. Sánchez-Rovira
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - A. Velasco
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - M. Dómine
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - F. Lobo
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - J. Oramas
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| | - J. Cruz
- Hospital Universitario de Canarias, La Laguna, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de La Princesa, Madrid, Spain
| |
Collapse
|
40
|
Rueda A, Sabin P, Rifá J, Llanos M, Gómez-Codina J, Lobo F, García-Arroyo R, Herrero J, Provencio M, Jara C. R-CHOP-14 in patients with diffuse large-B-cell lymphoma (DLBCL) younger than 70 years: A multicentric and prospective study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7592 Background: Several studies have shown that the addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisona), or shortening the interval between cycles of chemotherapy to two weeks, improves survival of patients with DLBCL. These studies prompted our group (GOTEL) to evaluate in a prospective study, the feasibility and efficacy of R-CHOP-14 in patients (pts) with DLBCL. Methods: Patients (younger than 70 years) with stage II bulky, III or IV DLBCL, and no significant co-morbidities were included in the study. R was administered on day 1 before chemotherapy. R-CHOP was recycled every 14 days. No antimicrobial prophylaxis was administered. All pts received filgrastim (5 μg/kg) from day +3 to +10. Pts received 6 cycles if CR was achieved after 3 cycles; those in PR, and those pts with bone marrow disease at diagnosis, received 8 cycles. Involved field radiation therapy was permitted for pts with stage II bulky disease. Results: From May 2002 to august 2004, 77 pts were included. Median age was 54 years (range, 15–70); 55 patients were younger than 60 years. According to the age adjusted International Prognostic Index (aaIPI), 13 pts (17%) had low risk disease, 27 pts (35%) low-intermediate risk, 29 pts (38%) high-intermediate risk, and 8 pts (10%) high risk disease. Grade 3–4 toxicity occurred as follow: neutropenia in 15 pts (19%), anaemia in 7 pts (9%), thrombocytopenia in 4 pts (5%), mucositis in 4 pts (5%) and peripheral neurotoxicity in 4 pts (5%). Ten pts were hospitalized (febrile neutropenia: 8 cases, one case of gastric perforation and one pulmonary embolism). After therapy, 61 pts (79%) achieved a CR/CRu (C.I. 95%: 57%-90%) and 14 pts (18%) a PR. 2 pts (3%) had refractory disease. With a median follow-up of 20 months, progression-free and overall survival at 24 months were 68% and 87%, respectively. Conclusions: Administration of R-CHOP-14 (with filgrastim support) is feasible and effective in patients younger than 70 years. [Table: see text]
Collapse
Affiliation(s)
- A. Rueda
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - P. Sabin
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - J. Rifá
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - M. Llanos
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - J. Gómez-Codina
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - F. Lobo
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - R. García-Arroyo
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - J. Herrero
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - M. Provencio
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - C. Jara
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| |
Collapse
|
41
|
Ferreira DA, Nunes CS, Antunes LM, Santos IA, Lobo F, Casal M, Ferreira L, Amorim P. The effect of a remifentanil bolus on the bispectral index of the EEG (BIS) in anaesthetized patients independently from intubation and surgical stimuli. Eur J Anaesthesiol 2006; 23:305-10. [PMID: 16469208 DOI: 10.1017/s0265021505001997] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/05/2005] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND OBJECTIVE Remifentanil boluses are used in different clinical situations and the effects on bispectral index monitoring are unclear. We analysed the effect of a remifentanil bolus on the bispectral index of the electroencephalogram (bispectral index) under total intravenous anaesthesia with propofol and remifentanil. METHODS ASA I-III patients were included in this study. All patients received a 2 microg k g-1 remifentanil bolus in a period free from stimuli. Bispectral index and haemodynamic data were collected from an A-2000XP bispectral index monitor (every second) and an AS/3 Datex monitor (every 5 s). Bispectral index data were analysed using the area under the curve. Mean arterial pressure and heart rate were averaged at each 30-s period and analysed using analysis of variance. RESULTS A total of 240 bispectral index values were obtained per patient. The area under the curve between 90 and 120 s after the bolus was significantly lower than the basal area under the curve (average of all areas before the bolus, P < 0.05). Mean arterial pressure and heart rate were significantly reduced from 96.4 +/- 19.9 mmHg at the time of the bolus to 74.2 +/- 16.6 mmHg 120 s after, and from 70 +/- 16.4 bpm at the time of the bolus to 61 +/- 13.6 bpm after (P < 0.001), respectively. CONCLUSIONS There was a significant reduction in the areas under the curve between 90-120 s following the bolus. Heart rate and blood pressure also showed significant reductions. Thus, remifentanil bolus given under total intravenous anaesthesia with propofol and remifentanil decreases bispectral index, an effect independent of intubation and surgical stimuli.
Collapse
Affiliation(s)
- D A Ferreira
- Universidade de Trás-os-Montes e Alto Douro, CECAV, Vila Real, Portugal.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Ferreira DA, Nunes CS, Antunes L, Lobo F, Amorim P. Practical aspects of the use of target controlled infusion with remifentanil in neurosurgical patients: predicted cerebral concentrations at intubation, incision and extubation. Acta Anaesthesiol Belg 2006; 57:265-70. [PMID: 17067138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Remifentanil has important side effects and it is not easy to know what remifentanil concentrations should be used during different endpoints of anaesthesia. We analyzed the remifentanil predicted effect-site concentrations (RemiCe) at different events during neurosurgical procedures and assessed if the concentrations used were clinically adequate. BIS and haemodynamic parameters were collected every 5 seconds. Predicted cerebral concentration of propofol (PropCe) and RemiCe were analyzed immediately prior to respective stimulus, and 30, 60 and 90 seconds after. RemiCe were 2.2 +/- 0.3, 6 +/- 2.6 and 2.2 +/- 0.9 ng ml(-1) at intubation, incision and extubation, respectively. PropCe observed in the same periods were 5 +/- 1, 2.6 +/- 0.9 and 1 +/- 0.3 microg ml(-1), also respectively. The remifentanil concentrations used in our patients were lower than reported concentrations, while being clinically adequate to minimize the haemodynamic response to stimulation.
Collapse
Affiliation(s)
- D A Ferreira
- Departamento de Matemática Aplicada, Faculdade de Ciências da Universidade do Porto, Portugal.
| | | | | | | | | |
Collapse
|
43
|
Lobo S, Lobo F, Polachini C, Patini D, Andraus K, Yamamoto A, Alvarez P, Sanchez H, Queiroz M, Teixeira S, Serrano P, Christiano A, Sivieiro E, Spegiorin M, Cunrath G, Oliveira N. Prospective, randomized trial comparing fluids and dobutamine optimization of oxygen delivery in high-risk surgical patients. Crit Care 2005. [PMCID: PMC4098194 DOI: 10.1186/cc3107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Jerónimo C, Henrique R, Oliveira J, Lobo F, Pais I, Teixeira MR, Lopes C. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol 2004; 57:872-6. [PMID: 15280411 PMCID: PMC1770387 DOI: 10.1136/jcp.2003.014555] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
AIMS Retinoids are involved in cell growth, differentiation, and carcinogenesis. Their effects depend on cytosolic transport and binding to nuclear receptors. CRBP1 encodes a protein involved in this process. Because altered CRBP1 expression and promoter hypermethylation occur in several tumours, these changes were investigated in prostate tumorigenesis. METHODS The CRBP1 promoter was assessed by methylation specific polymerase chain reaction on tissue samples from 36 radical prostatectomy specimens (paired normal tissue, adenocarcinoma, and high grade prostatic intraepithelial neoplasia (HGPIN)), 32 benign prostatic hyperplasias (BPHs), and 13 normal prostate tissue samples from cystoprostatectomies. Methylation of DNA extracted from microdissected tissue was examined blindly. CRBP1 expression was assessed by immunohistochemistry on formalin fixed, paraffin wax embedded tissue. RESULTS Loss of CRBP1 expression was seen in 15 of 36 adenocarcinomas and 18 of 36 HGPINs. Fifteen adenocarcinomas and nine HGPINs showed overexpression, whereas the remainder showed normal expression. BPH displayed normal expression. No significant associations were found between CRBP1 expression and Gleason score or stage. CRBP1 promoter hypermethylation was found in 17 of 36 adenocarcinomas, three of 35 HGPINs, one of 36 normal prostate tissues from the same patients, none of 32 BPHs, and none of 13 normal prostate tissues from cystoprostatectomies. Loss of expression and hypermethylation of CRBP1 were not significantly associated. CONCLUSIONS Altered CRBP1 expression and hypermethylation are common in prostate carcinoma, although CRBP1 hypermethylation is not an early event in tumorigenesis. Moreover, both adenocarcinoma and HGPIN show frequent CRBP1 overexpression. The molecular mechanisms underlying altered CRBP1 expression in prostate cancer deserve further study.
Collapse
Affiliation(s)
- C Jerónimo
- Department of Genetics, Portuguese Oncology Institute-Porto, Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.
| | | | | | | | | | | | | |
Collapse
|
45
|
Estevez LG, Batista N, Sánchez-Rovira P, Velasco A, Domine M, Lobo F, Oramas J, Cruz J. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.748] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. G. Estevez
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - N. Batista
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - P. Sánchez-Rovira
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - A. Velasco
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - M. Domine
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - F. Lobo
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - J. Oramas
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| | - J. Cruz
- Fundación Jimenez Diaz, Madrid, Spain; Hospital Universitario de Canarias, La Laguna (Tenerife), Spain; Hospital Universitario de Jaén, Jaén, Spain; Hospital de la Princesa, Madrid, Spain
| |
Collapse
|
46
|
Casado-Echarren VM, Abarrategui C, Alvarez R, Rubio G, León A, Dómine M, Calvo I, Estévez LG, López-Farré A, Lobo F. Effects of 5-fluorouracil on endothelial nitric oxide synthase in endothelial cells in different states of confluence. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - G. Rubio
- Fundacion Jimenez Diaz, Madrid, Spain
| | - A. León
- Fundacion Jimenez Diaz, Madrid, Spain
| | - M. Dómine
- Fundacion Jimenez Diaz, Madrid, Spain
| | - I. Calvo
- Fundacion Jimenez Diaz, Madrid, Spain
| | | | | | - F. Lobo
- Fundacion Jimenez Diaz, Madrid, Spain
| |
Collapse
|
47
|
Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimarães T, Bento MJ, Lobo F, Pinto S, Lopes C. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003; 14:1419-24. [PMID: 12954582 DOI: 10.1093/annonc/mdg377] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Of patients with superficial bladder cancer, a group are still at risk of disease recurrence, progression and death from their cancer after curative treatment. Angiogenesis is a crucial pathogenic mechanism for this type of urothelial cell carcinoma (UCC), and is a potential therapeutic target. However, the selection of the appropriate patients remains a dilemma. PATIENTS AND METHODS Vascular endothelial growth factor (VEGF) expression and the presence of angiogenesis and occurrence of CD31, CD34, endoglin and factor VIII immunoexpression, were evaluated in 66 superficial papillary UCCs of the bladder and were correlated with classical histopathological factors and disease outcome. RESULTS VEGF immunoreactivity was observed in 100% of cases, and more intensely in the luminal surface. The presence of microvessel clusters independently of a fibrovascular core was observed in 22.7% of cases. Of these, the T1/G2 subgroup had an independent and significantly lower recurrence-free survival (P = 0.0002). CONCLUSIONS These results indicate that the presence of angiogenesis in tumour urothelium is a potential prognostic factor in superficial UCC, particularly in T1/G2 tumours, and may be used to select patients for anti-angiogenic treatments.
Collapse
Affiliation(s)
- L Santos
- Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Domine M, Provencio M, Gomez R, Gonzalez Larriba J, Isla D, Terrasa J, Andrade J, Maeslu I, Estevez L, Lobo F. 782 CPT-11-Gemcitabine as second line chemotherapy in small cell lung cancer (SCLC). A multicentric phase II trial. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90807-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
49
|
Lobo F, Virizuela JA, Dorta FJ, Florián J, Lomas M, Jiménez E, López P, Casado V, Léon A, Estévez LG, Dómine M. Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer 2003; 4:46-50. [PMID: 12744758 DOI: 10.3816/cbc.2003.n.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This phase II study was designed to evaluate the response rate (RR) and toxicity of gemcitabine/vinorelbine in patients with metastatic breast cancer. All patients had previously received anthracyclines. Treatment consisted of gemcitabine 1200 mg/m2 and vinorelbine 30 mg/m2 on days 1 and 8, every 3 weeks. Twenty-five patients were enrolled. Median age was 59 years (range, 33-73 years). Ten patients had received only adjuvant therapy with anthracyclines. The remaining 15 patients had received chemotherapy for metastatic disease, including taxanes in 11 cases. Four patients could not be evaluated for response. By intent-to-treat analysis, the overall RR was 44% (95% CI, 24.4%-65%). Median duration of response and median time to treatment failure were 21 and 17 weeks, respectively. The main toxicity was hematologic, with grade 3/4 neutropenia occurring in 13 patients and 1 patient developing febrile neutropenia. Two deaths from pneumonia occurred. These results reveal an encouraging activity with a reasonable toxicity profile in a patient population with an unfavorable prognosis. Our group is conducting a randomized study to compare this combination with vinorelbine alone in patients with metastatic breast cancer after failure to respond to anthracyclines and taxanes
Collapse
Affiliation(s)
- F Lobo
- Fundación Jiménez Díaz, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Dómine M, Casado V, Estévez LG, León A, Martin JI, Castillo M, Rubio G, Lobo F. Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Semin Oncol 2001; 28:4-9. [PMID: 11510027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
The survival of patients with advanced non-small cell lung cancer remains poor. Cisplatin-based chemotherapy produces a modest benefit in survival compared with that observed with best supportive care. Gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN), a novel nucleoside antimetabolite, is active and well tolerated. The combination of gemcitabine/cisplatin has shown a significant improvement in response rate and survival over cisplatin alone. Phase III trials comparing gemcitabine/cisplatin with older combinations such as cisplatin/etoposide or mitomycin/ifosfamide/cisplatin have shown a higher activity for gemcitabine/cisplatin; however, the best way to combine these drugs remains unclear. In addition, the 3-week schedule has obtained a higher dose intensity with less toxicity and similar efficacy as the 4-week schedule. The role of carboplatin in combination with new drugs is still under evaluation. Gemcitabine/carboplatin seems to be a good alternative, with the advantage of ambulatory administration and lower nonhematologic toxicity. The 4-week schedule has produced frequent grade 3/4 neutropenia and thrombocytopenia in some studies. The 3-week schedule, using gemcitabine on days 1 and 8 and carboplatin on day 1, is a convenient and well-tolerated regimen. The toxicity profile is acceptable without serious symptoms. This schedule could be considered a good option as a standard regimen. Semin Oncol 28 (suppl 10):4-9.
Collapse
Affiliation(s)
- M Dómine
- Servicio de Oncología, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Av Reyes Católicos 2, 28040 Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|